All In Biotech

Free tool

FAERS Monitor: Bizengri

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761352 or its brand name (Bizengri, Zenocutuzumab-Zbco). Reports on generic versions are filed under their own applications.

Reports

10

Serious

4

40% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2
  • dysphonia2
  • infusion related reaction2
  • cardio-respiratory distress1
  • diarrhoea1
  • disease progression1
  • drug intolerance1
  • off label use1
  • product label confusion1
  • product strength confusion1
  • product use issue1
  • rash maculo-papular1
  • sepsis1
  • thrombocytopenia1

Reports by year received

View as table
YearReports
20256
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product strength confusion1110811.316359.626,317
cardio-respiratory distress17387.41146.51,839
product label confusion1360.956.289
rash maculo-papular194.514.723
dysphonia271.920.878
infusion related reaction263.518.469
drug intolerance121.83.45
sepsis118.92.94
thrombocytopenia118.82.94
disease progression117.82.84
product use issue111.21.72
diarrhoea13.30.50
drug ineffective23.20.91
off label use12.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.